🔗 Share this article

The first new treatments for gonorrhoea in a generation are being viewed as a "huge turning point" in the battle against increasingly resistant strains of the bacteria, according to health experts.

A Worldwide Challenge

Gonorrhoea infections are escalating worldwide, with estimates suggesting over 82 million instances annually. Notably increased rates are reported in Africa and nations within the World Health Organization's Western Pacific region, which includes Mongolia and China to New Zealand. Within England, cases have reached a historical peak, while figures across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The clearance of fresh medications for gonorrhoea is an significant and necessary step in the face of rising global incidence, escalating drug resistance and the very limited available drugs at this time.”

Medical experts are increasingly worried about the increase in antibiotic-resistant strains. The WHO has designated it as a "priority pathogen". Recent surveillance found that resistance to key first-line drugs like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Recent Treatment Options Secure Clearance

One new antibiotic, alternatively called Nuzolvence, was approved by the US Food and Drug Administration in mid-December for use against gonorrhoea. This disease can lead to significant complications, including the inability to conceive. Scientists anticipate that specific application of this new drug will help delay the development of resistance.

Another new antibiotic, created by the pharmaceutical company GlaxoSmithKline, was also approved in the same week. This drug, which is employed against urinary tract infections, was proven in research to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin was the result of a innovative non-profit model for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company Innoviva to bring it to fruition.

“This milestone signifies a major breakthrough in the management of highly resistant gonorrhoea, which up to this point has been outpacing medical innovation.”

Research Study Outcomes and Worldwide Availability

Based on findings detailed in a major medical journal, zoliflodacin successfully treated more than 90% of uncomplicated infections. This places it at an similar efficacy with the typical regimen, which involves two antibiotics. The trial included hundreds of patients from multiple nations including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its unique model, the non-profit has the rights to register and commercialise the drug in numerous regions with limited resources.

Doctors on the front lines have voiced optimism. Having a one-pill regimen of this kind is hailed as a "critical tool" for managing the epidemic. This is viewed as vital to alleviate the strain of the illness for patients and to halt the transmission of untreatable gonorrhoea around the world.